Literature DB >> 3745889

The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis.

N Gitlin, D C Lewis, L Hinkley.   

Abstract

Thirty-seven patients, all with histologic evidence of cirrhosis and with a normal neurological examination and normal mental status were evaluated by psychometric testing for subclinical hepatic encephalopathy. They were all regarded as having well compensated cirrhosis, not requiring any treatment or dietary restrictions and they were working, and many of them driving. A group of 19 patients with a history of alcoholism, or medical disorders, but without clinical or biochemical evidence of cirrhosis, served as controls. They were matched by age, sex, education, and alcohol consumption. Investigations performed were an EEG, fasting arterial ammonia, liver biochemical tests and a series of verbal and performance psychometric tests. The EEG was abnormal in 3 (8.3%) of patients, the ammonia elevated in 17 (45.9%) of patients and 26 patients (70.3%) failed 2 or more psychometric tests, as compared to 2 (10.5%) of the control group. It is concluded that 2 out of 3 patients with stable, well compensated cirrhosis were suffering from subclinical hepatic encephalopathy and that impairment of performance rather than verbal skills occurred. The digital symbol test, trail test (number connection test) and block design tests readily identified the patients with subclinical hepatic encephalopathy. The implication of these observations in patients with cirrhosis, especially those working in mechanical or skilled occupations, needs consideration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3745889     DOI: 10.1016/s0168-8278(86)80149-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

Review 1.  Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management.

Authors:  T Gerber; H Schomerus
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.

Authors:  E A Jones; V I Giger-Mateeva; D Reits; F C Riemslag; B Liberov; H Spekrijse
Journal:  Metab Brain Dis       Date:  2001-06       Impact factor: 3.584

3.  Correlations between cerebral glucose metabolism and neuropsychological test performance in nonalcoholic cirrhotics.

Authors:  Alan H Lockwood; Karin Weissenborn; Martin Bokemeyer; U Tietge; Wolfgang Burchert
Journal:  Metab Brain Dis       Date:  2002-03       Impact factor: 3.584

4.  Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.

Authors:  R K Dhiman; M S Sawhney; Y K Chawla; G Das; S Ram; J B Dilawari
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

Review 5.  EEG and event related potentials in hepatic encephalopathy.

Authors:  M G Davies; M J Rowan; J Feely
Journal:  Metab Brain Dis       Date:  1991-12       Impact factor: 3.584

6.  Memory impairment in patients with cirrhosis.

Authors:  Funda Bahceci; Bulent Yildirim; Melih Karincaoglu; Ibrahim Dogan; Birsen Sipahi
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

Review 7.  Encephalopathy in Wilson disease: copper toxicity or liver failure?

Authors:  Peter Ferenci; Tomasz Litwin; Joanna Seniow; Anna Czlonkowska
Journal:  J Clin Exp Hepatol       Date:  2014-09-22

8.  Evaluation of neuropsychological function in patients with liver cirrhosis with special reference to their driving ability.

Authors:  A Watanabe; T Tuchida; Y Yata; Y Kuwabara
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

9.  Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy.

Authors:  P Amodio; P Marchetti; F Del Piccolo; G Sartori; M Prior; C Merkel; A Gatta
Journal:  Metab Brain Dis       Date:  1995-12       Impact factor: 3.584

Review 10.  Neuropsychological aspects of liver disease and its treatment.

Authors:  R E O'Carroll
Journal:  Neurochem Res       Date:  2007-10-24       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.